Brief: Therapeutic Solutions Says It Will Use Clinical Stage Cancer Immunotherapy For Covid-19
22/06/2020 14:11
June 22 (Reuters) - Therapeutic Solutions International Inc
TSOI.PK :
* THERAPEUTIC SOLUTIONS INTERNATIONAL ANNOUNCES INTENTION TO
USE
CLINICAL STAGE NK ACTIVATING CANCER IMMUNOTHERAPY FOR COVID-19
* THERAPEUTIC SOLUTIONS INTERNATIONAL - FILES PATENT ON
FDA-PENDING STEMVACS DENDRITIC CELL THERAPY FOR BOOSTING OF
COVID-19 IMMUNITY
Source text for Eikon: ID:nPn7gmkXHa
Further company coverage: TSOI.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Therapeutic Solutions International
See all newsBrief: Therapeutic Solutions International Files For Orphan Drug Designation Use Of Jadicell Adult Stem Cells
Brief: Therapeutic Solutions International Files To Initiate Phase Iii Clinical Trial For Acute Respiratory Distress Syndrome (ARDS) Leveraging Positive Covid-19 Data With Jadicell Stem Cell Therapy
Brief: Therapeutic Solutions International Files With FDA To Expand Ongoing Phase III Clinical Trial To Include All Causes Of Acute Respiratory Distress Syndrome
Brief: Therapeutic Solutions Granted Emergency IND By FDA For Stem Cell Therapy
Brief: Therapeutic Solutions International Completes Purchase Of FDA Phase Iii Jadicell Stem Cell Investigational New Drug Application From University Of Miami